IonQ and Quantum Computing Inc. both build quantum equipment, but one stands out as the superior investment. The field of quantum computing is exciting. Quantum computers use atomic particles to perform complex calculations beyond the abilities of today's supercomputers, positioning them to revolutionize numerous industries. Quantum Computing Inc. takes a different approach. It embraces the inherent chaos of harnessing these particles in a technique called entropy quantum computing. This method allows QCi's ...

That said, if you are looking for potential upside with reduced volatility than standalone stocks, the Trefis High Quality portfolio offers an alternative — having surpassed the S&P 500 and yielding returns greater than 91% since its launch. In addition, see – Bigbear.ai: Sell BBAI Stock At $5? See earnings reaction history of all stocks CHONGQING, CHINA - MAY 11: In this photo illustration, the logo of Quantum Computing Inc. (QCi) is displayed on a smartphone screen, with the company's branding visible in ...

D-Wave Quantum stock has been getting a healthy amount of positive coverage from analysts lately. D-Wave Quantum (QBTS 2.78%) stock posted another month of strong gains in July's trading. The company's share price jumped 17.4% in the month. For reference, the S&P 500 index's level rose 2.2% in the month, and the Nasdaq Composite gained 3.7%. D-Wave stock gained ground last month amid generally bullish momentum for growth stocks and continued excitement surrounding quantum computing plays. The company's shar ...

Core Viewpoint - Quantum BioPharma Ltd. is seeking shareholder approval for a non-brokered private placement of class A multiple voting shares for gross proceeds of up to $600 million, with the meeting scheduled for September 26, 2025 [1][2]. Group 1: Offering Details - The entire offering is expected to be subscribed by existing holders of MVS and is anticipated to close on or about September 26, 2025, pending shareholder approval [2]. - Proceeds from the offering will be used for general working capital purposes [2]. - All securities issued will be subject to a statutory hold period of four months plus a day from issuance in accordance with Canadian securities laws [2]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [5]. - The company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation, a key factor in multiple sclerosis, and is currently in preclinical models [5]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement of 7% on sales until total payments reach $250 million, after which the royalty will drop to 3% [5].

Core Insights - D-Wave Quantum reported mixed earnings results with revenue growth exceeding analyst expectations but wider-than-expected losses [1][2] - Despite the mixed results, D-Wave's stock performance remains strong, with shares up nearly 20% in the last month [2] Financial Performance - D-Wave experienced a 42% year-over-year revenue increase, with bookings nearly doubling to $1.3 million [3] - The company ended the quarter with $819 million in cash reserves, positioning it well for future technological advancements and potential M&A strategies [5] Market Position and Competitors - D-Wave's marketability is bolstered by partnerships with a large aerospace and defense firm and law enforcement in North Wales, indicating growing use cases for its technology [4] - In comparison, IonQ reported an 81.6% year-over-year revenue increase, reaching $20.7 million for the quarter, which is significantly higher than D-Wave's growth rate [7][8] - IonQ's expanding global presence and partnerships with major tech firms like Amazon and Microsoft may pose competitive challenges for D-Wave [10] Future Outlook - D-Wave's Advantage2 system is now generally available, which is expected to drive additional sales and upgrades for existing customers [3] - Quantum Computing, another competitor, is set to report earnings soon and has operationalized a new foundry in Arizona, which could enhance its revenue growth [13][14]

Core Insights - D-Wave Quantum (QBTS) is launching an open-source Quantum AI Toolkit integrated with PyTorch, enabling hybrid quantum-classical machine learning workflows, which enhances traditional AI methods with quantum computing capabilities [1][8] - The toolkit is already being utilized by early adopters like Japan Tobacco and Triumph for optimization and generative AI applications, with ongoing R&D to expand quantum AI capabilities [2] - D-Wave is also advancing its strategic infrastructure through initiatives like the Cryogenic Packaging Initiative with NASA, aimed at developing superconducting chip-to-chip interconnects for scaling to 100,000-qubit systems [3] - The company is scaling manufacturing with superconducting PCB advanced packaging and increasing wafer fabrication runs, positioning itself for both AI applications and next-generation quantum computing hardware [4] - D-Wave's shares have increased by 57.7% over the past three months, outperforming industry averages, with analysts projecting a further upside of 17.06% based on average price targets [4][10] Industry Context - Competitors in the quantum computing space include IonQ, which is focusing on hybrid AI model training and has made significant acquisitions to enhance its capabilities [7] - Rigetti Computing has achieved a breakthrough with a modular 36-qubit chiplet-based system, indicating advancements in the modular superconducting architecture strategy within the industry [9]

Quantum stocks grabbed the attention of investors and analysts last week as second-quarter earnings reports came in. Here's a look at what happened in the quantum computing sector. D-Wave Quantum Last Thursday, D-Wave Quantum Inc QBTS reported second-quarter revenue of $3.1 million, beating analyst estimates of $2.63 million, but missed top-line expectation with a larger than expected loss per share. Following the print, Needham analyst N. Quinn Bolton reiterated a Buy rating on D-Wave Quantum with a $20 pr ...

Company Overview - Quantum Computing Inc. (QCi) is an innovative company specializing in integrated photonics and quantum optics technology, providing accessible and affordable quantum machines and foundry services for photonic chip production based on thin-film lithium niobate (TFLN) [4] - The company's products are designed to operate at room temperature and low power, making them cost-effective [4] - QCi's technology portfolio includes capabilities in high-performance computing, artificial intelligence, cybersecurity, and remote sensing applications [4] Upcoming Events - QCi will host a conference call and webcast on August 14, 2025, at 4:30 p.m. Eastern Time to review its operational progress for the second quarter ended June 30, 2025 [1] - The company will release its second quarter 2025 financial results on the same day after the market closes [1] Access Information - Investors can access the live webcast through the QCi Investor Relations page or via a specific link provided [2] - For phone participation, a specific dial-in number and access code are provided for both domestic and international callers [2] Replay Information - A replay of the teleconference will be available until August 28, 2025, with specific dial-in numbers and conference ID for access [3]

Core Insights - Quantum BioPharma Ltd. has signed an agreement with a leading contract development and manufacturing organization (CDMO) to manufacture an oral drug formulation of Lucid-MS, which will be used in the upcoming Phase 2 clinical trial for multiple sclerosis (MS) [1][3] - Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound that has shown potential in preclinical models to prevent demyelination, a key characteristic of MS [2] - The company is preparing an Investigational New Drug (IND) application with the FDA as part of its clinical development strategy for Lucid-MS [3] Company Overview - Quantum BioPharma is focused on developing innovative therapies for neurodegenerative disorders and has a portfolio of drug candidates at various stages of development [4] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement of 7% on sales until total payments reach $250 million, after which the royalty will decrease to 3% [4] - Quantum BioPharma also maintains strategic investments through its subsidiary, FSD Strategic Investments Inc., which involves loans secured by residential or commercial property [4]

Companies exposed to the quantum computing revolution can deliver transformative returns in the coming years. The artificial intelligence (AI)-fueled technology revolution has taken the world by storm. However, quantum computing is now promising to be the next paradigm-shifting technology. This transformative technology aims to reshape computational capabilities across every industry. Despite the high future growth potential, monetization opportunities in quantum computing are still limited. Therefore, it m ...